Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository (HS PROGRESS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04115566 |
Recruitment Status :
Recruiting
First Posted : October 4, 2019
Last Update Posted : June 6, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Hidradenitis Suppurativa |
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 3000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 10 Years |
Official Title: | Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository |
Actual Study Start Date : | August 1, 2020 |
Estimated Primary Completion Date : | September 1, 2029 |
Estimated Study Completion Date : | September 1, 2029 |

- Primary Objective [ Time Frame: 2019-2029 ]The primary aim of this study is to identify clinical and biologic characteristics of hidradenitis suppurativa.
- Secondary Objective [ Time Frame: 2019-2029 ]Secondary aims include correlating alterations in clinical and biological characteristics with disease status, and identifying genetic variants that predict disease progression or response to therapy.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 10 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Male or female ≥ 10 years of age
- Diagnosis of HS by a dermatologist or practitioner experienced in making a diagnosis of HS
- Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
Exclusion Criteria:
1. Inability to give informed consent or unavailability of a parent/guardian who is able and willing to give informed consent.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04115566
Contact: Hannah Balter | 415-502-4741 | hannah.balter@ucsf.edu |
United States, California | |
University of California San Francisco | Recruiting |
San Francisco, California, United States, 94115 | |
Principal Investigator: Haley B Naik, MD, MHSc, FAAD |
Principal Investigator: | Haley B Naik, MD, MHSc, FAAD | University of California, San Francisco |
Responsible Party: | University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT04115566 |
Other Study ID Numbers: |
18-27002 |
First Posted: | October 4, 2019 Key Record Dates |
Last Update Posted: | June 6, 2022 |
Last Verified: | June 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Hidradenitis Suppurativa Hidradenitis Sweat Gland Diseases Skin Diseases Skin Diseases, Bacterial |
Bacterial Infections Bacterial Infections and Mycoses Infections Skin Diseases, Infectious Suppuration |